IL250905B - Predictive and diagnostic biomarkers associated with anti-angiogenic therapy of metastatic colon cancer - Google Patents

Predictive and diagnostic biomarkers associated with anti-angiogenic therapy of metastatic colon cancer

Info

Publication number
IL250905B
IL250905B IL250905A IL25090517A IL250905B IL 250905 B IL250905 B IL 250905B IL 250905 A IL250905 A IL 250905A IL 25090517 A IL25090517 A IL 25090517A IL 250905 B IL250905 B IL 250905B
Authority
IL
Israel
Prior art keywords
predictive
colorectal cancer
metastatic colorectal
angiogenic therapy
prognostic biomarkers
Prior art date
Application number
IL250905A
Other languages
English (en)
Hebrew (he)
Other versions
IL250905A0 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL250905A0 publication Critical patent/IL250905A0/en
Publication of IL250905B publication Critical patent/IL250905B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL250905A 2014-09-16 2017-03-02 Predictive and diagnostic biomarkers associated with anti-angiogenic therapy of metastatic colon cancer IL250905B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051091P 2014-09-16 2014-09-16
US201562099630P 2015-01-05 2015-01-05
PCT/US2015/049279 WO2016044041A1 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Publications (2)

Publication Number Publication Date
IL250905A0 IL250905A0 (en) 2017-04-30
IL250905B true IL250905B (en) 2019-12-31

Family

ID=54207741

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250905A IL250905B (en) 2014-09-16 2017-03-02 Predictive and diagnostic biomarkers associated with anti-angiogenic therapy of metastatic colon cancer

Country Status (12)

Country Link
US (2) US10525104B2 (enExample)
EP (1) EP3194974B1 (enExample)
JP (1) JP6692358B2 (enExample)
KR (1) KR102471057B1 (enExample)
CN (1) CN107076749B (enExample)
AU (1) AU2015318207B2 (enExample)
CA (1) CA2960890A1 (enExample)
EA (1) EA036671B1 (enExample)
IL (1) IL250905B (enExample)
MX (1) MX382673B (enExample)
WO (1) WO2016044041A1 (enExample)
ZA (1) ZA201701664B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11699527B2 (en) 2013-03-14 2023-07-11 Otraces, Inc. Method for improving disease diagnosis using measured analytes
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP6952056B2 (ja) 2016-01-22 2021-10-20 オートレイシーズ, インク.Otraces, Inc. 疾患診断を改善するシステム及び方法
CA3058129C (en) * 2017-03-31 2023-04-18 Hirotsu Bio Science Inc. Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
JP2022541689A (ja) * 2019-07-13 2022-09-26 オートレイシーズ,インク. 腫瘍微小環境活性蛋白質を用いる種々の疾患の診断の改善
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
IN2012DN02046A (enExample) * 2009-08-14 2015-08-21 Allergan Inc
CN102711830A (zh) 2010-01-19 2012-10-03 霍夫曼-拉罗奇有限公司 用于贝伐单抗联合疗法的基于肿瘤组织的生物标志
SG10201505593VA (en) * 2010-07-19 2015-09-29 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)

Also Published As

Publication number Publication date
EA036671B1 (ru) 2020-12-07
WO2016044041A1 (en) 2016-03-24
AU2015318207A1 (en) 2017-04-06
EA201790549A1 (ru) 2017-07-31
US10525104B2 (en) 2020-01-07
CN107076749B (zh) 2020-12-29
EP3194974B1 (en) 2019-10-23
MX382673B (es) 2025-03-13
ZA201701664B (en) 2018-05-30
MX2017003387A (es) 2018-01-30
JP2017530372A (ja) 2017-10-12
JP6692358B2 (ja) 2020-05-13
AU2015318207B2 (en) 2021-11-04
KR102471057B1 (ko) 2022-11-28
IL250905A0 (en) 2017-04-30
CA2960890A1 (en) 2016-03-24
KR20170055972A (ko) 2017-05-22
EP3194974A1 (en) 2017-07-26
CN107076749A (zh) 2017-08-18
US20200129589A1 (en) 2020-04-30
US20170281725A1 (en) 2017-10-05
US11439683B2 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
ZA201701664B (en) Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
SG11201607448PA (en) Determining cancer agressiveness, prognosis and responsiveness to treatment
GB2545361B (en) Methods of assessing colorectal cancer status
IL253756B (en) A panel of biomarkers for cancer detection
ZA201701753B (en) Biomarkers for assessing breast cancer
IL244510A0 (en) Cancer biomarkers and their uses
EP3245302B8 (en) Mirna-based predictive models for diagnosis and prognosis of prostate cancer
IL251204A0 (en) Biomarkers and predictive methods
IL267315A (en) Methods of determining colorectal cancer status in an individual
ZA201802481B (en) Novel biomarkers and methods of treating cancer
GB201500584D0 (en) Cancer biomarkers
GB201322800D0 (en) Prostate cancer biomarkers
IL242551A (en) Expectation markers for cancer treatment
SG11201601234TA (en) Circulating cancer biomarker and its use
GB201417281D0 (en) Methods and devices relating to the detection of oral cancer biomarkers
EP2972376A4 (en) Methods for determining prognosis of colorectal cancer
GB201619808D0 (en) Biomarkers for the prognosis and diagnosis of cancer
SG10202103525UA (en) Cancer biomarkers and methods of use
GB201617722D0 (en) Method for determining prognosis of cancer
GB201306394D0 (en) Cancer biomarker
PL3268744T3 (pl) PD-ECGF jako biomarker raka
EP3060914A4 (en) Methods of determining breast cancer prognosis
GB201411393D0 (en) Agents and methods for determining colorectal cancer status
GB201413577D0 (en) Metastatic prognostic biomarker
GB201407003D0 (en) Biomarkers for prostate cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed